Submission of Transcript of Valueportal Event held on Tuesday January 20, 2026 at 14:00 P.M.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Earkart Limited, a hearing aid and audiology company founded in 2021, shared business updates with investors through a virtual event. The company manufactures hearing aids and has developed a patented remote diagnostic machine called 'Omni', which is currently placed at 80+ ENT clinics with audiologists at Earkart's command centre conducting tests remotely. Last year (FY25) turnover was ₹43 crore and H1 FY26 already at ₹23 crore, giving the company roughly 7-8% market share in hearing aids by units. Management plans to scale to 1,500 Omni clinics over the next 3 years, with a capex of about ₹3 lakh per clinic. Gross margins vary significantly by channel: 35-37% for government sales, 40-45% for B2B, and 65-70% for the SIS (shop-in-shop) B2C model. The company is exploring expansion into the US, Australia and Africa, is in active licensing discussions with 3 large companies for Omni, and has a proposed acquisition of Turtle Marks LLP aimed at armed forces markets pending board approval.
Positive long-term narrative for shareholders — high-margin SIS model scaling, international expansion plans and a potential acquisition point to strong growth runway. However, the actual ramp-up from 80 to 1,500 clinics and overseas entry will require sustained execution and capital deployment, so near-term stock reaction may depend on upcoming board approval for the Turtle Marks deal and progress on licensing tie-ups.